49 results about "Methicillin resistance" patented technology

The invention discloses a lyase for killing staphylococcus and an application of the lyase and also discloses an amino acid sequence and an encoding gene sequence of the lyase. A recombined lyase constructed by using the disclosed encoding gene can realize soluble expression in Escherichia coli BL21 (DE3); the lyase can be used for efficiently killing various types of staphylococcus including clinically-separated methicillin-sensitive staphylococcus aureus (MSSA) and methicillin-resistant staphylococcus aureus (MRSA) in vitro and can also be used as an antibiotic for treating staphylococcus infection in vivo; and the disclosed lyase can also be used for rapidly cracking the cell wall of the staphylococcus and releasing substances in cells, such as adenosine triphosphate (ATP), DNA (Deoxyribonucleic Acid) and the like, and various detections on the staphylococcus can be realized through detecting released substances.

The invention relates to a kit for quickly detecting a drug resistance gene of pneumophila pathogenic bacteria, which comprises a gene chip capable of detecting 24 main drug resistance genes of pneumophila pathogenic bacteria and a reaction system for multiple asymmetric PCR reactions. The 24 drug resistance genes are derived from aminoglycosides, quinolones, extended spectrum beta-lactamases (ESBLs), cephalosporins (AmpC), carbapenems and drug resistance genes with vancomycin resistance and methicillin resistance causing membrane permeability transition. The kit can be used for directly detecting drug resistance genes of pneumophila pathogenic bacteria in clinical samples, is simple and quick to operate, does not need culture or drug sensitive tests, gains valuable time for reasonable application of antibiotics to a great extent, and is worthy of clinical popularization and application.

The invention belongs to the technical fields of molecular biological techniques and clinical tests, and particularly discloses a nosocomial infection multiple causative agent parallel detection gene chip and a preparation method and application thereof. The gene chip can be used for rapidly and sensitively detecting fourteen medical treatment infection typical causative agents such as acinetobacter baumannii, enterobacter cloacae, enterococcus faecalis and the like by using one reaction, and the detection data of coinfection of yeast and bacterium which cannot be provided by a traditional amplification method is offered. Furthermore, the gene chip also comprises a methicillin resistance target spot, thus realizing further detection of staphy lococcus infection, therefore, a clinician can realize which causative agent a patient is infected in one or two hours, and realize whether the patient has drug resistance, so as to decide whether the patient needs antibiotics or which antibiotics is needed, so that the gene chip has a greater clinical guiding significance.

The present application relates generally to a method and a composition matter that provides a rapid and potent antimicrobial photodynamic inactivation (aPDI) of pathogenic bacteria that express high-affinity cell-surface hemin receptors (CSHRs) using Ga(III)-protoporphyrins IX (GaPpIX or Ga-PpIX). The invention provides an effective treatment option for infections of skin or body cavities that are accessible to visible-light irradiation, such as a handheld LED array emitting visible light (405 nm), especially for infections caused by Staphylococcus aureus, Methicillin-resistant Staphylococcus aureus (MRSA), pathogenic staphylococci, Streptococcus mutans, S. pneumoniae, S. pyogenes, streptococci, corynebacteria, mycobacteria, and Bacillus anthracis.

MRSA CC398 is a clone of S. aureus that has recently emerged in pigs and other domestic animals worldwide. As any other MRSA, the clone displays high levels of antibiotic resistance and poses a serious threat to human health because of the risk of antibiotic treatment failure in human patients. We developed a new diagnostic test for identification of MRSA CC398 using a single one-step PCR that is very easily performed within a few hours. The test is based on the principle that clonal differences within S. aureus are reflected in the sequence of a gene (sau1hsdS1) located on the chromosome of this bacterial species. Accordingly, such a gene represents an optimal target for S. aureus and MRSA identification at the clone level. The test includes detection of the gene conferring methicillin resistance (mecA), therefore allowing rapid discrimination between methicillin-susceptible and methicillin-resistant variants of the clone. A preliminary validation of the test was performed on a collection of CC398 and non-CC398 strains, resulting in 100% sensitivity and 100% specificity. The test can be combined to real-time PCR technology to further reduce simplify the test performance as well as to allow quantification of the target MRSA clone in biological specimens. The invention has important applications related to surveillance and control of MRSA CC398 in humans, animals and food products.

The invention discloses a primer for detecting methicillin-resistant staphylococcus aureus. The primer comprises a primer body for amplifying a methicillin-resistant mecA medicine resistant gene, a primer body for amplifying a staphylococcus aureus nuc gene, a fluorescent probe T1 for detecting the methicillin-resistant mecA medicine resistant gene and a fluorescent probe T2 for detecting the staphylococcus aureus nuc gene. The nucleotide sequence is shown as SEQ ID NO:1-6. The invention further discloses a kit comprising the primer for detecting the methicillin-resistant staphylococcus aureus. The primer and the kit are suitable for rapidly detecting methicillin-resistant staphylococcus aureus strains in a suspicious staphylococcus aureus infected person clinic sample, and have the advantages of being high in sensitivity and specificity, stable, timely, convenient to operate and the like.

The invention discloses an orixine derivative and an application of orixine derivative in preparation of medicine for resisting drug-fast bacteria, the test shows that the orixine derivative is capable of inhibiting breeding of a plurality of drug-fast bacterium in vitro, and can be used for preparing antibiotic medicines for resisting drug-fast bacteria; the orixine derivative is used for preparing medicines for resisting methicillin-resistant staphylococcus aureus (MRSA), preparing medicines for resisting benzylpenicillin-resistant staphylococcus aureus, and preparing medicines for resisting vancomycin-resistant enterococcus; the medicines can be prepared to the injection, tablet, pill, capsule, a suspending agent or an emulsion for usage, a chemical structural formula of the orixine derivative is shown in formula I, wherein R1,R2 and R3 are defined in a specification.

The present invention relates to compounds and methods of treating, preventing, or lessening the severity of drug-resistant Gram-positive bacterial infections in mammals. The compounds consist of a combination of a gyrase B inhibitor and a protein synthesis inhibitor. These compounds demonstrate antibacterial activity against drug-resistant strains of Gram-positive bacteria, and in particular, methicillin-resistant Staphylococcus aureus (MRSA). Methods for inhibiting the activity of strains of Gram-positive bacteria and methods for treating a bacterial infection caused by such organisms are described herein.

The invention specifically relates to gorgonian-originated fungus secondary metabolite derivatives and application of the same as antiseptics, belonging to the field of medicine. The derivatives provided by the invention exert strong inhibitory effect on methicillin-resistant staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE) and certain inhibitory effect on Gram-negative bacteria; and the minimal inhibition concentrations MIC of the derivatives are all less than 12.5 mu M, which proves that the derivatives can be developed into potential antibacterial drugs.

The present invention relates to an antibody against a protein specifically expressed in methicillin-resistant strains of Staphylococcus aureus (MRSA), and a method and a kit for detecting MRSA. The present invention enables a fast and accurate detection of MRSA by using both a PBP2a-specific antibody for the detection of PBP2a and a Protein A-specific antibody for the detection of Protein A.

The invention relates to the technical field of biotechnology, in particular to a primer probe combination for identification of staphylococcus aureus and drug resistance of staphylococcus aureus. Theprimer probe combination provided by the invention comprises general primer and probe targeting staphylococcus aureus and specific primer and probe targeting methicillin-resistant staphylococcus aureus.The primer and probe has good specificity and can achieve rapid, accurate and sensitive identification targeting SA and MRSA combined with real-time PCR detection method. Experiments show that minimum detection limit of the primer probe for detection of staphylococcus aureus is 3 CF/ml and minimum detection limit of the primer probe for detection of methicillin-resistant staphylococcus aureus is 5 CF/ml.

The present invention relates to a novel antimicrobial compound of lactoquinomycin that is highly effective against many antibiotic-resistant gram-positive bacteria; namely, methicillin-resistant and vancomycin-resistance Staphylococcus aureus, vancomycin-resistant Enterococcus faecilis and Mycobacteria. The present invention also relates to a fermentation process of culturing a Streptomyces strain to prepare the antimicrobial compound and its use in killing the antibiotic-resistant bacteria.

The invention discloses amycolamycin as well as a preparation method thereof and application thereof. The amycolamycin is from a liquid fermentation product of endophytic actinomycetes Amycolatopsis sp.HCa4 in the intestinal tract of asiatic migratory locust, and comprises amycolamycin A or amycolamycin B. According to the experimental research results, the amycolamycin has very strong antibacterial activity on methicillin-resistant staphylococcus epidermidis staphylococcus aureus, has very strong cytotoxic activity on human breast cancer cells M231, can be prepared into a novel anti-tumour lead compound, and overcomes the drug resistance defect of existing antibiotics to a certain extent.

By culturing Lysobacter sp. BMK333-48F3 (deposit number of FERM BP-7477), an antibiotic, tripropeptin Z, tripropeptin A, tripropeptin B, tripropeptin C or tripropeptin D represented by the general formula (I):

wherein R is 7-methyl-octyl group, 8-methyl-nonyl group, 9-methyl-dodecyl group, 10-methyl-undecyl group or 11-methyl-dodecyl group, is obtained as antibiotics having excellent antibacterial activities against bacteria and having a novel molecular structure. These tripropeptins each have an excellent antibacterial activity against various bacteria and drug-resistant strains thereof, such as methicillin-resistant strains and vancomycin-resistant strains.

Belonging to the technical field of drug research and development, the invention in particular relates to an anti-tumor and antibacterial compound and application thereof. The anti-tumor and antibacterial compound is named as dialboflavusin A or de-Cl-dialboflavusin A. The anti-tumor and antibacterial compounds dialboflavusin A and de-Cl-dialboflavusin A have strong bacteriostatic activity on 7 gram positive bacteria for test: Bacillus subtilis, Bacillus cereus, Staphylococcus aureus, and four different methicillin-resistant Staphylococcus aureus strains. The anti-tumor and antibacterial compounds dialboflavusin A and de-Cl-dialboflavusin A have strong inhibiting effect on cervical cancer cell line Hela, human ovarian adenocarcinoma cell line SKOV3, human breast cancer cell line MCF-7, human lung cancer cell line A549, human hepatoma cell line HepG2, human glioma cell line U251 and human gastric carcinoma cell line SGC-7901. The anti-tumor and antibacterial compound provided by the invention can be used for study of anti-tumor active lead compounds or preparation of antibacterial and anti-tumor drugs.

The invention belongs to the technical field of medicine chemistry, and discloses an aromatic phenol antibacterial peptide simulant with anti-drug resistance activity and no obvious toxicity and a preparation method thereof. The target product is obtained through a reaction of 3 to 4 steps, and the main structure is shown below. Vitro antibacterial activity experiment proves that most of the compounds have good activity on gram-positive bacteria staphylococcus aureus and enterococcus faecalis, gram-negative bacteria large intestine angstrom bacillus and notrophomonas maltophilia, and shows that the compounds have excellent broad-spectrum antibacterial activity; meanwhile, the extracorporeal red blood cell hemolytic data shows that the toxicity is small, and the method has good selectivity.Part of the compounds shows excellent antibacterial activity in superbacteria including methicillin-resistant staphylococcus aureus (MRSA), NDM-1 and KPC-2 enzyme. Therefore, the compounds are expected to be used as a new antibacterial candidate drug.